Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a charcoal pill delay dialysis?

NCT ID NCT00500682

Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tested whether AST-120, a spherical carbon adsorbent taken as a powder, can slow the progression of chronic kidney disease. Over 1,000 adults with moderate to severe kidney disease received either AST-120 or a placebo alongside their usual care. The main goal was to see if the drug could delay the need for dialysis, kidney transplant, or a doubling of creatinine levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AST-120 (spherical carbon adsorbent)
What this could lead to
If it works, this could provide a new way to delay dialysis or kidney transplant in people with moderate to severe chronic kidney disease.
What could go wrong
This is a completed Phase 3 trial, but results may not show a clear benefit over standard care. The treatment is an adsorbent, not a cure, and long-term safety needs confirmation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,020 people

The number who actually took part.

Start date

Jul 2007

Finished

Oct 2011

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Moderate to severe CKD, not anticipated to require dialysis or renal transplant within the next 6 months * Patient survival expected to be no less than one year * Serum creatinine in men \>= 2.0 mg/dL (\>= 177 µmol/L) and \<= 5.0 mg/dL (\<= 442 µmol/L), and in women \>= 1.5 mg/dL (\>= 133 µmol/L) and \<= 5.0 mg/dL (\<= 442 µmol/L) at Screening * Urinary total protein to urinary total creatinine ratio must be \>= 0.5 on a spot void at Screening * Blood pressure \<= 160/90 mmHg at both Screening and Baseline. In addition, blood pressure, if measured, must have been stable in hypertensive patients over the 3 months prior to Screening, with no more than 1 blood pressure reading \> 160/90 mmHg * In patients being treated for hypertension, they should be on a stable anti-hypertensive regimen Exclusion Criteria: * Obstructive or reversible cause of kidney disease * Nephrotic syndrome defined as a ratio of urinary total protein to urinary creatinine of \> 6.0 as measured on a spot void * Adult polycystic kidney disease * History of previous kidney transplant * History of recent (within the past 6 months) accelerated or malignant hypertension * Uncontrolled arrhythmia or severe cardiac disease within the past 6 months * History of malabsorption, inflammatory bowel disease, hiatal hernia, active peptic ulcer, or severe GI dysmotility, not attributable to the use of a phosphate binder * Received any investigational agent or participated in a clinical study within the previous 3 months * Presence of any significant medical condition that might create an undue risk with study participation, or significantly confound the collection of safety and efficacy data in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease

Contacts and locations

Locations

  • Study site

    Phoenix, Arizona, United States

  • Study site

    Little Rock, Arkansas, United States

  • Study site

    Alhambra, California, United States

  • Study site

    Covina, California, United States

  • Study site

    Glendale, California, United States

  • Study site

    Los Angeles, California, United States

  • Study site

    Stamford, Connecticut, United States

  • Study site

    Washington D.C., District of Columbia, United States

  • Study site

    Hudson, Florida, United States

  • Study site

    Miami, Florida, United States

  • Study site

    Ocala, Florida, United States

  • Study site

    Orlando, Florida, United States

  • Study site

    Pembroke Pines, Florida, United States

  • Study site

    Spring Hill, Florida, United States

  • Study site

    Tampa, Florida, United States

  • Study site

    Winter Park, Florida, United States

  • Study site

    Kansas City, Kansas, United States

  • Study site

    New Orleans, Louisiana, United States

  • Study site

    Shreveport, Louisiana, United States

  • Study site

    Ypsilanti, Michigan, United States

  • Study site

    Kansas City, Missouri, United States

  • Study site

    St Louis, Missouri, United States

  • Study site

    Camden, New Jersey, United States

  • Study site

    Eatontown, New Jersey, United States

  • Study site

    Port Washington, New York, United States

  • Study site

    Springfield Gardens, New York, United States

  • Study site

    Asheville, North Carolina, United States

  • Study site

    Cincinnati, Ohio, United States

  • Study site

    Dayton, Ohio, United States

  • Study site

    Toledo, Ohio, United States

  • Study site

    Portland, Oregon, United States

  • Study site

    Philadelphia, Pennsylvania, United States

  • Study site

    Pittsburgh, Pennsylvania, United States

  • Study site

    Rock Hill, South Carolina, United States

  • Study site

    Nashville, Tennessee, United States

  • Study site

    Arlington, Texas, United States

  • Study site

    Dallas, Texas, United States

  • Study site

    Houston, Texas, United States

  • Study site

    San Antonio, Texas, United States

  • Study site

    Appleton, Wisconsin, United States

  • Study site

    Oshkosh, Wisconsin, United States

  • Study site

    Buenos Aires, Argentina

  • Study site

    Córdoba, Argentina

  • Study site

    San Luis, Argentina

  • Study site

    San Miguel de Tucumán, Argentina

  • Study site

    San Pedro, Argentina

  • Study site

    Barao Geraldo-Campinas, Brazil

  • Study site

    Belo Horizonte Minas Gerais, Brazil

  • Study site

    Juiz de Fora, Brazil

  • Study site

    Porto Alegre, Brazil

  • Study site

    Rio de Janeiro, Brazil

  • Study site

    São Paulo, Brazil

  • Study site

    Taubaté, Brazil

  • Study site

    Winnipeg, Manitoba, Canada

  • Study site

    Brampton, Ontario, Canada

  • Study site

    Kitzhener, Ontario, Canada

  • Study site

    Oakville, Ontario, Canada

  • Study site

    Scarborough Village, Ontario, Canada

  • Study site

    Toronto, Ontario, Canada

  • Study site

    Montreal, Quebec, Canada

  • Study site

    České Budějovice, Czechia

  • Study site

    Jihlava, Czechia

  • Study site

    Ostrava - Poruba, Czechia

  • Study site

    Prague, Czechia

  • Study site

    Tábor, Czechia

  • Study site

    Grenoble, France

  • Study site

    Lyon, France

  • Study site

    Nantes, France

  • Study site

    Saint-Lô, France

  • Study site

    Bologna, Italy

  • Study site

    Brescia, Italy

  • Study site

    Como, Italy

  • Study site

    Pavia, Italy

  • Study site

    Aguascalientes, Mexico

  • Study site

    Mexico City, Mexico

  • Study site

    Tijuana, Mexico

  • Study site

    Gdansk, Poland

  • Study site

    Szczecin, Poland

  • Study site

    Torun, Poland

  • Study site

    Warsaw, Poland

  • Study site

    Caguas, Puerto Rico

  • Study site

    Bamaul, Russia

  • Study site

    Kazan', Russia

  • Study site

    Krasnodar, Russia

  • Study site

    Moscow, Russia

  • Study site

    Nizhny Novgorod, Russia

  • Study site

    Novosibirsk, Russia

  • Study site

    Pyatigorsk, Russia

  • Study site

    Ryazan, Russia

  • Study site

    Saint Petersburg, Russia

  • Study site

    Saratov, Russia

  • Study site

    Smolensk, Russia

  • Study site

    Sochi, Russia

  • Study site

    Stavropol, Russia

  • Study site

    Yekaterinburg, Russia

  • Study site

    Chernivtsi, Ukraine

  • Study site

    Dnipropetrovsk, Ukraine

  • Study site

    Donetsk, Ukraine

  • Study site

    Ivano-Frankivsk, Ukraine

  • Study site

    Kharkiv, Ukraine

  • Study site

    Kiev, Ukraine

  • Study site

    Odesa, Ukraine

  • Study site

    Uzhhorod, Ukraine

  • Study site

    Vinnitsa, Ukraine

  • Study site

    Zhytomyr, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.